MICHELLE DIMAURO: Open Payments
NPI 1760935373 · DANBURY, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,632 in 88 payments from 14 companies in 2025. Trend: 2023 $1,833 · 2024 $1,842 · 2025 $1,632
Food & beverage: $1,632
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 30 | $336 |
| AstraZeneca Pharmaceuticals LP | 12 | $299 |
| GENZYME CORPORATION | 8 | $215 |
| Amgen Inc. | 9 | $166 |
| Novartis Pharmaceuticals Corporation | 7 | $141 |
| Regeneron Healthcare Solutions, Inc. | 7 | $138 |
| CSL Behring | 4 | $89 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $86 |
| ARS Pharmaceuticals Operations, Inc. | 2 | $39 |
| Optinose US, Inc. | 2 | $38 |
Products named: DUPIXENT, NUCALA, TEZSPIRE, AIRSUPRA, Rhapsido, Andembry, BREZTRI, NEFFY.
Industry payments across CT — which companies pay providers there.
